Pharma industry warns lower generic prices will curb R&D, health officials cite unchanged pricing since 2012 Korea’s pharmaceutical industry is bracing for a major clash with the government over a proposed cut to generic drug prices, warning the move …

… commitment to cost efficiency, Indian drugmakers have anchored the global generics … , biotech represents a much higher degree of reward and risk at … , Director Scientific Affairs, United States Pharmacopeia (USP)-India; Lakshminarayana Neti, Chief …

… negligence and corruption within the pharmaceutical sector documented by international agencies … more dangerous is the degree to which Indian pharmaceutical multinationals have embedded … in the first place. Indian drugmakers can retain U.S. dominance …

This year, cross-border deals in China’s innovative drug sector have accelerated, with artificial intelligence-driven firms emerging as key players. Syneron, Helixon, and XtalPi illustrate the trend, together closing business development (BD) transactions …

Since the Ministry of Food and Drug Safety (MFDS) introduced the “One-Strike-Out” system for violations of Good Manufacturing Practice (GMP) standards in December 2022, eight pharmaceutical companies have had their GMP compliance certifications revoked. …

… comical degree. Biogen, a $20 billion US drugmaker specialising … percent duties on branded pharmaceuticals, which will come into … for specific products like pharmaceuticals. The new 100 percent … Shares in large listed pharmaceutical companies in Europe barely …

… examine the situation facing drugmakers. In March, President Donald … and that could give pharma marketers a degree of flexibility, given … become a target. Moreover, drugmakers are feeling political pressure … Letters sent to 17 drugmakers last month by the …

… issued draft recommendations for drugmakers interested in developing new … It also details how drugmakers should test their experimental … “We sense a high degree of FDA interest in … expects companies, including Xenon Pharmaceuticals and Rapport Therapeutics, to …

… , underscores growing unease among global drugmakers about Britain’s regulatory and … Europe in the competition for pharmaceutical innovation and capital. Jamie Young … business reporting. Jamie holds a degree in Business Administration and regularly …

… takes to become a successful drugmaker. Mikael Dolsten, former CSO, … theoretical. But experts in pharma and tech are optimistic that … discern to a greater degree which outputs make sense … pharma partners like Pfizer as well as with dozens of smaller drugmakers …